临床误诊误治
臨床誤診誤治
림상오진오치
CLINICAL MISDIAGNOSIS & MISTHERAPY
2015年
6期
66-69
,共4页
癌,非小细胞肺%老年人%替吉奥胶囊%贞芪扶正胶囊
癌,非小細胞肺%老年人%替吉奧膠囊%貞芪扶正膠囊
암,비소세포폐%노년인%체길오효낭%정기부정효낭
Carcinoma,Non-small-cell lung%Aged%Gimeracil Capsule%Zhen stilbene righting capsule
目的：探讨替吉奥胶囊联合贞芪扶正胶囊治疗老年非小细胞肺癌的临床效果。方法选择75岁以上的非小细胞肺癌患者66例,随机分为观察组32例及对照组34例。观察组予替吉奥胶囊联合贞芪扶正胶囊治疗（替吉奥胶囊40~60 mg、2/d口服,治疗14 d,休息7 d；贞芪扶正胶囊6粒、2/d口服)。对照组予消癌平胶囊联合贞芪扶正胶囊治疗（消癌平胶囊4~5粒、3/d口服,贞芪扶正胶囊6粒、2/d口服)。3周为1个周期,两组均用药6个周期评价近期疗效,之后继续服药至不能耐受停止用药为止,随访至死亡,观察远期疗效。结果观察组疾病控制率（ DCR)为75．0%,对照组DCR为11．8%,两组比较差异有统计学意义（P<0．01)；观察组疾病进展时间（TTP)（3．42±1．21)个月、总生存期（OS)（13．94±2．53)个月、1年生存率34．4%,对照组TTP（0．83±0．42)个月、OS（7．62±1．35)个月、1年生存率8．8%,两组比较差异均有统计学意义（P<0．05)；两组血液毒性反应及胃肠道毒性反应发生率比较差异无统计学意义（P>0．05)。结论替吉奥胶囊联合贞芪扶正胶囊治疗老年非小细胞肺癌安全有效。
目的：探討替吉奧膠囊聯閤貞芪扶正膠囊治療老年非小細胞肺癌的臨床效果。方法選擇75歲以上的非小細胞肺癌患者66例,隨機分為觀察組32例及對照組34例。觀察組予替吉奧膠囊聯閤貞芪扶正膠囊治療（替吉奧膠囊40~60 mg、2/d口服,治療14 d,休息7 d；貞芪扶正膠囊6粒、2/d口服)。對照組予消癌平膠囊聯閤貞芪扶正膠囊治療（消癌平膠囊4~5粒、3/d口服,貞芪扶正膠囊6粒、2/d口服)。3週為1箇週期,兩組均用藥6箇週期評價近期療效,之後繼續服藥至不能耐受停止用藥為止,隨訪至死亡,觀察遠期療效。結果觀察組疾病控製率（ DCR)為75．0%,對照組DCR為11．8%,兩組比較差異有統計學意義（P<0．01)；觀察組疾病進展時間（TTP)（3．42±1．21)箇月、總生存期（OS)（13．94±2．53)箇月、1年生存率34．4%,對照組TTP（0．83±0．42)箇月、OS（7．62±1．35)箇月、1年生存率8．8%,兩組比較差異均有統計學意義（P<0．05)；兩組血液毒性反應及胃腸道毒性反應髮生率比較差異無統計學意義（P>0．05)。結論替吉奧膠囊聯閤貞芪扶正膠囊治療老年非小細胞肺癌安全有效。
목적：탐토체길오효낭연합정기부정효낭치료노년비소세포폐암적림상효과。방법선택75세이상적비소세포폐암환자66례,수궤분위관찰조32례급대조조34례。관찰조여체길오효낭연합정기부정효낭치료（체길오효낭40~60 mg、2/d구복,치료14 d,휴식7 d；정기부정효낭6립、2/d구복)。대조조여소암평효낭연합정기부정효낭치료（소암평효낭4~5립、3/d구복,정기부정효낭6립、2/d구복)。3주위1개주기,량조균용약6개주기평개근기료효,지후계속복약지불능내수정지용약위지,수방지사망,관찰원기료효。결과관찰조질병공제솔（ DCR)위75．0%,대조조DCR위11．8%,량조비교차이유통계학의의（P<0．01)；관찰조질병진전시간（TTP)（3．42±1．21)개월、총생존기（OS)（13．94±2．53)개월、1년생존솔34．4%,대조조TTP（0．83±0．42)개월、OS（7．62±1．35)개월、1년생존솔8．8%,량조비교차이균유통계학의의（P<0．05)；량조혈액독성반응급위장도독성반응발생솔비교차이무통계학의의（P>0．05)。결론체길오효낭연합정기부정효낭치료노년비소세포폐암안전유효。
Objective To discuss the clinical effect of Gimeracil Capsule combined with Zhen Stilbene Righting cap-sules in treatment of senile patients with non-small cell lung cancer. Methods 66 non-small cell lung cancer patients ( 75 years old and over) were randomly divided into observation group (32 cases) and control group(34 cases). Observation group received Gimeracil capsules combined with Zhen Stilbene Righting capsules,Gimeracil capsules 40-60 mg / each time, two times per day for 14 days and then rested for 7 days. 6 Zhen Stilbene Righting capsules were given each time, two times per day. Control group received Eliminate cancer Flat capsules combined with Zhen Stilbene Righting capsules, Eliminate cancer flat capsules ( 4-5 grains/each time), three times per day, Zhen Stilbene Righting capsules, (6 grains/each time), two times per day. Three weeks was a cycle, and there were 6 cycles and the curative effect was reviewed. The medication contin-ued until the patient was not able to tolerate and then it was stopped. A follow-up was carried out till the patients died. Re-sults Statistically significant difference between the two groups was observed with the disease control rates ( DCR ) ( P <0. 01). The rate of the observation group was 75. 0%, whereas that of the control group was 11. 8%. The time to progression (TTP), the overall survival(OS)and the 1-year survival rate of the observation group were (3. 42 ± 1. 21) months,(13. 94 ± 2. 53)months and 34. 4% respectively, whereas that in the control group were (0. 83 ± 0. 42) months,(7. 62 ± 1. 35) months and 8. 8%. Statistically significant difference was observed between the two groups(P<0. 05). But there was no statistically significant difference between the blood toxicity reaction and gastrointestinal toxicity reaction of the two groups ( P>0. 05 ) . Conclusion Gimeracil Capsule combined with Zhen Stilbene Righting Capsules is safe and effective in the treatment of senile non-small cell lung cancer.
